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Seventy-eight blood cultures with a Gram stain result of Gram-positive cocci in pairs and/or chains were evaluated with the
Nanosphere Verigene Gram-positive blood culture (BC-GP) assay. The overall concordance of the assay with culture was 89.7%
(70/78 cultures), allowing for the development of a targeted treatment algorithm.
Bloodstream infections (BSI) are a leading cause of morbidityand mortality. In 2009, BSI were the cause of nearly 36,000
deaths in the United States (1). Health care-associated BSI are a
major contributor to these statistics, being associated with nearly
75,000 infections a year with a mortality rate of approximately
25% (2). Enterococci are the third leading cause of health care-
associated BSI (3), and inappropriate antimicrobial therapy has
been shown to be an independent risk factor for the increased
mortality of BSI (4). The Nanosphere Verigene Gram-positive
blood culture (BC-GP) assay (Nanosphere, Northbrook, IL) is an
on-demand FDA-cleared test for the identification of 15 targets
from positive blood culture bottles. Previous studies have shown
this assay to be an effective method for determining the identity of
Gram-positive organisms, showing 92 to 95% overall concor-
dance for organism identification (5, 6); however, the implemen-
tation of an algorithm for treatment based on BC-GP test results
has not been proposed. The current work focuses on the perfor-
mance of the assay specifically in cultures where streptococci and
enterococci are suspected based on the primary Gram stain and on
the algorithm we have developed for treatment based on the
BC-GP results.
We first performed an evaluation of the BC-GP assay on the
Nanosphere Verigene system. Routine blood cultures were col-
lected using FAN aerobic (FA), pediatric FAN (PF), and standard
anaerobic (SA) bottles and subsequently incubated on the BacT/
Alert (bioMérieux, Durham, NC) system. Positive blood cultures
were Gram stained, plated onto solid medium, and stored upright
at 35°C for up to 5 days. Subcultures were evaluated according to
standard laboratory protocols, and organisms were identified us-
ing a combination of morphological and phenotypic methods as
well as matrix-assisted laser desorption ionization–time of flight
(MALDI-TOF) mass spectrometry (Vitek MS; bioMérieux). No-
tably, the Vitek MS accurately distinguishes between Streptococcus
pneumoniae and Streptococcus mitis/Streptococcus oralis (7). Posi-
tive blood cultures with a Gram stain of Gram-positive cocci in
pairs and/or chains were further evaluated with the BC-GP assay
according to the manufacturer’s recommendations. The BC-GP
targets analyzed include Enterococcus faecalis, Enterococcus fae-
cium, Streptococcus spp., Streptococcus agalactiae, Streptococcus an-
ginosus group, S. pneumoniae, Streptococcus pyogenes, and the re-
sistance determinants vanA and vanB.
Seventy-eight consecutive positive blood cultures from 74 pa-
tients with an initial Gram stain result containing Gram-positive
cocci in pairs and/or chains were evaluated with the BC-GP assay,
of which 72 had at least one target detected. Of the six cultures for
which no target was detected, three grew organisms (Acinetobacter
sp., Atopobium sp., B. cereus group) for which the assay does not
target, and two grew Streptococcus vestibularis, which has not been
evaluated by the manufacturer according to the package insert.
The remaining negative BC-GP cultures grew five different organ-
isms (Enterococcus faecalis, Enterococcus gallinarum, Enterobacter
cloacae, Candida tropicalis, and Klebsiella pneumoniae) on subcul-
ture. See Table 1 for a complete list of organisms that were not
detected by the BC-GP assay.
The BC-GP assay performed comparably to routine isolate
identification; no target had more than three errors (Table 2). S.
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Klebsiella pneumoniaea 3 3
Stenotrophomonas maltophiliaa 2 1
Bacillus cereus groupa 2 1
Streptococcus vestibularis 2 2
Rothia spp.a 2 0
Atopobium spp. 1 1
Enterococcus faecalis 1 1
Enterobacter cloacaea 1 1
Candida tropicalisa 1 1
Enterococcus gallinaruma 1 1
Acinetobacter spp. 1 1
Serratia marcescensa 1 1
Actinomyces spp.a 1 1
a Component of polymicrobial culture.
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agalactiae and S. pyogenes demonstrated 100% agreement between
BC-GP and culture identification. The Streptococcus spp. target
had 96.2% agreement with isolate identification. One discordant
result was a culture that grew a pyrrolidonyl arylamidase (PYR)-
negative alpha-hemolytic organism presumptively identified as
viridans group Streptococcus by our laboratory; confirmatory test-
ing was not performed, and the blood culture bottle gave a result
of Enterococcus faecium by the BC-GP assay. The other two discor-
dant results were two cultures that grew an organism identified as
Streptococcus vestibularis by MALDI-TOF MS. Although the man-
ufacturer lists S. vestibularis as an organism for which the perfor-
mance of the BC-GP has not been evaluated, two additional cul-
tures that grew S. vestibularis were positive for the Streptococcus
species target. All S. vestibularis isolates were from distinct patients
and were detected using both FA and SN media, indicating poten-
tial target variability in different strains of S. vestibularis. S. angi-
nosus group also had one discordant result (98.7% agreement),
which was a culture that grew an organism identified by MALDI-
TOF MS as Streptococcus mitis/S. oralis, but the BC-GP assay gave
a dual result of S. anginosus group and S. pneumoniae. This was
one of two S. mitis/S. oralis cultures that gave an identification of S.
pneumoniae by the BC-GP assay, equating to 97.4% agreement for
the S. pneumoniae target. In total, eight cultures grew S. mitis/S.
oralis; the other six were correctly identified by the BC-GP assay as
Streptococcus species only. The two cultures that grew S. pneu-
moniae were correctly identified as such by the BC-GP assay. The
only culture that grew an organism that was claimed to be in-
cluded by the manufacturer yet did not generate a positive result
by the BC-GP assay was a culture with an initial polymicrobial
Gram stain which grew E. faecalis, E. gallinarum, Enterobacter clo-
acae, Candida tropicalis, and Klebsiella pneumoniae. This was also
the only discordant result for the E. faecalis target and the only
discordant polymicrobial culture. Fourteen cultures grew more
than one organism, 13 (92.3%) of which were concordant with the
BC-GP result. Nine of the 14 polymicrobial cultures grew organ-
isms that are not detected by the BC-GP assay (Table 1). In our
study, 10 cultures grew organisms that were phenotypically iden-
tified as vancomycin-resistant enterococci (VRE), and all had
vanA detected by the BC-GP assay. Additionally, there was a cul-
ture that grew vancomycin-susceptible E. faecium, for which the
vanA target was positive. The patient who was the source of this
culture had a history of VRE-positive rectal screens as well as a
concurrent urine sample from which VRE was isolated. Based on
the data above, the overall concordance of the BC-GP assay with






Streptococcus spp. 39 96.2 (75/78)
Streptococcus agalactiae 7 100 (78/78)
Streptococcus anginosus 5 98.7 (77/78)
Streptococcus pneumoniae 2 97.4 (76/78)
Streptococcus pyogenes 1 100 (78/78)
Enterococcus faecalis 18 98.7 (77/78)
Enterococcus faecium 16 98.7 (77/78)
Vancomycin resistance (vanA) 10 97.0 (32/33)
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FIG 1 Algorithm for treatment recommendations based on BC-GP assay result.
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isolate identification was 89.7%, which notably includes two false-
negative results observed with S. vestibularis identified as the
Streptococcus species target, which is not claimed to be included by
the manufacturer.
Based on the performance of the assay during our evaluation
period, we were able to develop a treatment algorithm in consul-
tation with our antimicrobial stewardship program. For improved
algorithm utilization, the results of the BC-GP assay are commu-
nicated directly to an on-call pharmacist and entered into the
patient’s electronic medical record. The algorithm illustrated in
Fig. 1 is used as a guide for the pharmacist when recommending
therapy. Patients whose cultures are positive by the BC-GP assay
for S. pyogenes, S. agalactiae, and S. anginosus group are recom-
mended to receive penicillin or ceftriaxone with or without clin-
damycin (clindamycin is recommended for patients with signs of
septic shock). Ceftriaxone was not our empirical therapy of choice
for S. pneumoniae, due to a 73% susceptibility rate at our institu-
tion. Reduced susceptibility, along with the false-positive results
for the S. pneumoniae target due to S. mitis/S. oralis, led us to
recommend vancomycin for empirical therapy for infection with
S. pneumoniae along with other Streptococcus spp. not identified to
the species level. We note that while we chose to specifically rec-
ommend daptomycin for vancomycin-intolerant patients, a rec-
ommendation or requirement for infectious disease consultation
would be suitable as well. Importantly, early detection of VRE is
critical to aid in the switch from a vancomycin-based treatment
regimen. Lastly, based on our data, we do not recommend that
cultures with mixed Gram stain results (e.g., Gram-negative rods
and Gram-positive cocci in pairs/chains, or Gram-positive cocci
in clusters and Gram-positive cocci in pairs/chains) be evaluated
by the BC-GP assay in conjunction with the recommended treat-
ment algorithm.
Our data support previous findings that the Nanosphere
BC-GP assay accurately identifies targets from positive blood cul-
tures, with the exception of the differentiation of S. mitis/S. oralis
and S. pneumoniae (5, 6). False-positive S. pneumoniae results do
not limit the utility of the assay, as we were still able to develop a
treatment algorithm to promote the use of targeted regimens
based on the results generated by the BC-GP assay. Although we
have previously shown that a pharmacy-based intervention strat-
egy is effective at our institution (8), the effectiveness of our
BC-GP algorithm for streptococci and enterococci will need to be
measured.
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